RVMD

162.0651.65%
MA

Mark A. Goldsmith

CEO, President & Chairman

Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman since 2020. Dr. Goldsmith served as a Venture Partner at Third Rock Ventures, LLC since joining in 2012. Previously, he was a Partner at Third Rock Ventures since 2013. Dr. Goldsmith served as an Interim Chief Executive Officer of Nurix, Inc. Dr. Goldsmith served as the Interim Chief Executive Officer of Global Blood Therapeutics, Inc until June 2014. Dr. Goldsmith was a Venture Partner. Dr. Goldsmith served as an Assistant Director of the Gladstone Institute of Virology and Immunology of J. David Gladstone Institutes. He held senior executive positions in the biotechnology industry and academia. He led the development of an industry-leading strategic alliance with Genentech and remains active as its Chairman. He served as Chief Executive Officer of Constellation Pharmaceuticals where he led the creation of its oncology pipeline and drove the development of a strategic alliance with Genentech. Prior to his appointment at Constellation in 2009, he served as a Senior Executive-in-Residence at Prospect Venture Partners. He co-founded Cogentus Pharmaceuticals, Inc. and served as its Chairman, Chief Executive Officer and President. Dr. Goldsmith served as a Senior Vice President of Health Care at Danisco US Inc. since June 18, 2003. He has consulted extensively in the biotechnology and pharmaceutical industries. Dr. Goldsmith joined Genencor in 2001 from the faculty of the University of California at San Francisco (UCSF) and the Gladstone Institute of Virology and Immunology, where he was a distinguished physician-scientist who led a major research program in the areas of immunologic and virologic diseases. Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the University of California, San Francisco School of Medicine and at San Francisco General Hospital and was a Consultant to leading pharmaceutical and biotechnology companies. He practiced medicine on the faculty of the University of California, San Francisco School of Medicine and at San Francisco General Hospital. He served as the Independent Chairman of the Board at Constellation Pharmaceuticals, Inc. since 2009 until July 15, 2021, where he served as the Chief Executive Officer since August 2009 and served as its President. He served as the Chairman of the Board at Nurix, Inc since September 2014 until May 3, 2016. Dr. Goldsmith serves as Director at Igenica, Inc. He serves as Director at Nura Bio, Inc. He served as a Director of Global Blood Therapeutics, Inc. until September 2014. He served as a Director of Cogentus Pharmaceuticals, Inc. He has great experience in the life sciences. He plays an instrumental role in the ideation, development and leadership of new companies. Dr. Goldsmith received his A.B. in biology from Princeton University and conducted postgraduate medical training in Medical Science at Harvard Medical School and the University of California, San Francisco. He earned his M.D. and Ph.D. in Microbiology and Immunology from the University of California, San Francisco.

Positions